IMARC Group, a leading market research company, has recently releases report titled “Hemoglobinopathies Market Report by Type (Thalassemia, Sickle Cell Disease, and Others), Treatment (Blood Transfusion, Stem-cell Transplantation, Analgesics, Antibiotics, ACE Inhibitors, Hydroxyurea, and Others), Test Type (Red Blood Cell (RBC) Count, Genetic Testing, High Performance Liquid Chromatography (HPLC), Hemoglobin Isoelectric Focusing (Hb IEF), Hemoglobin Electrophoresis (Hb ELP), Hemoglobin Solubility Test), End User (Hospitals and Clinics, Diagnostics Laboratories, and Others), and Region 2024-2032”, Offers a comprehensive analysis of the industry, which comprises insights on the global hemoglobinopathies market share.

How Big is the Hemoglobinopathies Market ?

The global hemoglobinopathies market size reached US$ 10.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 21.3 Billion by 2032, exhibiting a growth rate (CAGR) of 8.5% during 2024-2032.

Industry Overview of Hemoglobinopathies

Hemoglobinopathies refer to a group of genetic disorders characterized by abnormalities in the structure or production of hemoglobin, the protein required for transporting oxygen in red blood cells (RBCs). They are caused by genetic mutations and can be categorized into various types, including sickle cell disease and thalassemia. They are characterized by various symptoms, including a shortage of healthy RBCs, pale skin, yellowing of the skin and eyes, and enlargement of the spleen. They are treated by blood transfusions, bone marrow transplants, and folic acid supplementation. They can also be cured  by hydroxyurea, which increases the production of fetal hemoglobin and pain medications for pain.

Request Sample Copy of This Report : https://www.imarcgroup.com/hemoglobinopathies-market/requestsample

What are the Growth Prospects and Trends in the Hemoglobinopathies Industry ? :

At present, increasing advancements in genetic research and diagnostics for identifying and characterizing various hemoglobinopathies represent one of the crucial factors impelling the growth of the market.

Besides this, the rising focus on early detection and intervention, ultimately improving patient outcomes, is propelling the growth of the market. In addition, the growing gene therapy and gene modifying systems, such as clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, are positively influencing the market.

Apart from this, increasing investments in the development and commercialization of hemoglobinopathy treatments by the governing agencies of various countries and pharmaceutical companies are supporting the growth of the market.

Leading Companies Operating in the Global Hemoglobinopathies Industry:

• Bio-Rad Laboratories Inc.
• bluebird bio Inc.
• Bristol-Myers Squibb Company
• Danaher Corporation
• Emmaus Life Sciences Inc.
• Gamida-Cell Ltd.
• Global Blood Therapeutics Inc.
• Novartis AG
• PerkinElmer Inc.
• Pfizer Inc.
• Prolong Pharmaceuticals LLC
• Sangamo Therapeutics Inc.
• Sysmex Corporation

Hemoglobinopathies Market Report Segmentation:

Breakup by Type:

• Thalassemia
  • Alpha Thalassemia
  • Beta Thalassemia
• Sickle Cell Disease
• Others

Breakup by Treatment:

• Blood Transfusion
• Stem-cell Transplantation
• Analgesics
• Antibiotics
• ACE Inhibitors
• Hydroxyurea
• Others

Breakup by Test Type:

• Red Blood Cell (RBC) Count
• Genetic Testing
• High Performance Liquid Chromatography (HPLC)
• Hemoglobin Isoelectric Focusing (Hb IEF)
• Hemoglobin Electrophoresis (Hb ELP)
• Hemoglobin Solubility Test

Breakup by End User:

• Hospitals and Clinics
• Diagnostics Laboratories
• Others

Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145

Browse Other Research Reports:

Solar Encapsulation Market
Aerospace Foam Market
Artificial Intelligence Chip Market